Universe Pharmaceuticals Inc. (UPC) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: 3.07
30Y Low3.1·High3.1
P/FCF
N/A
—
5yr avg: 3.14
30Y Low3.1·High3.1
P/B Ratio
↓
0.00
↓-100% vs avg
5yr avg: 0.23
30Y Low0.0·High0.8
ROE
↓
-7.2%
-19% vs avg
5yr avg: -6.1%
30Y Low-21%·High79%
Debt/EBITDA
N/A
—
5yr avg: 0.31
30Y Low0.2·High0.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
UPC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Universe Pharmaceuticals Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $14608 | $889673 | $3M | $12M | $47M | — | — | — |
| Enterprise Value | $-22673259 | $-24320498 | $-20613834 | $4M | $10M | $43M | — | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | 4.14 | — | — | — |
| P/S Ratio | 0.09 | 0.00 | 0.04 | 0.10 | 0.30 | 0.98 | — | — | — |
| P/B Ratio | 0.00 | 0.00 | 0.02 | 0.09 | 0.26 | 0.80 | — | — | — |
| P/FCF | — | — | — | 3.14 | — | — | — | — | — |
| P/OCF | — | — | — | 3.01 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
UPC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -1.36 | -0.90 | 0.11 | 0.26 | 0.90 | — | — | — |
| EV / EBITDA | — | — | — | — | — | 3.07 | — | — | — |
| EV / EBIT | — | — | — | — | — | 3.13 | — | — | — |
| EV / FCF | — | — | — | 3.32 | — | — | — | — | — |
UPC Profitability
Margins and return-on-capital ratios measuring operating efficiency
Universe Pharmaceuticals Inc. earns an operating margin of -16.3%. Operating margins have compressed from -10.9% to -16.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -7.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.3% | 35.3% | 26.4% | 31.9% | 54.5% | 52.8% | 45.9% | 40.3% | 47.0% |
| Operating Margin | -16.3% | -16.3% | -34.8% | -10.9% | -17.5% | 28.3% | 33.4% | 29.4% | 33.9% |
| Net Profit Margin | -20.6% | -20.6% | -37.9% | -19.1% | -21.8% | 23.6% | 24.6% | 22.7% | 26.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -7.2% | -7.2% | -20.5% | -14.3% | -16.6% | 28.4% | 45.5% | 68.4% | 78.5% |
| ROA | -5.4% | -5.4% | -14.4% | -10.9% | -13.5% | 22.9% | 32.4% | 32.9% | 27.1% |
| ROIC | -7.8% | -7.8% | -18.9% | -6.3% | -10.5% | 29.7% | 61.2% | 82.0% | 118.5% |
| ROCE | -5.6% | -5.6% | -18.4% | -8.2% | -13.3% | 34.1% | 61.8% | 88.4% | 99.7% |
UPC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $34M exceeds total debt of $9M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.16 | 0.16 | 0.18 | 0.14 | 0.08 | 0.07 | 0.13 | 0.20 | 0.27 |
| Debt / EBITDA | — | — | — | — | — | 0.31 | 0.25 | 0.25 | 0.26 |
| Net Debt / Equity | — | -0.43 | -0.47 | 0.00 | -0.04 | -0.06 | -0.36 | -0.05 | -0.37 |
| Net Debt / EBITDA | — | — | — | — | — | -0.27 | -0.70 | -0.06 | -0.35 |
| Debt / FCF | — | — | — | 0.18 | — | — | -1.22 | -0.05 | -0.83 |
| Interest Coverage | -14.83 | -14.83 | -28.19 | -23.55 | -42.68 | 135.63 | 82.61 | 75.67 | 58.71 |
Net cash position: cash ($34M) exceeds total debt ($9M)
UPC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Universe Pharmaceuticals Inc.'s current ratio of 4.07x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.68x to 4.07x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.07 | 4.07 | 2.54 | 2.68 | 3.17 | 4.50 | 2.85 | 2.24 | 1.19 |
| Quick Ratio | 3.90 | 3.90 | 2.46 | 2.43 | 3.00 | 4.28 | 2.62 | 1.76 | 0.75 |
| Cash Ratio | 2.55 | 2.55 | 1.45 | 1.35 | 1.44 | 1.94 | 1.26 | 0.58 | 0.34 |
| Asset Turnover | — | 0.26 | 0.34 | 0.61 | 0.67 | 0.68 | 1.07 | 1.86 | 1.02 |
| Inventory Turnover | 5.27 | 5.27 | 9.76 | 6.58 | 8.27 | 9.20 | 8.71 | 7.58 | 1.86 |
| Days Sales Outstanding | — | 269.50 | 283.40 | 121.21 | 138.06 | 120.27 | 129.24 | 70.53 | 97.76 |
UPC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Universe Pharmaceuticals Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | 211.9% | 40.2% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 24.1% | — | — | — |
| FCF Yield | — | — | — | 31.9% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $3478 | $6077 | $5923 | $5923 | $5272 | $5833 | $5833 | $5833 |
Peer Comparison
Compare UPC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 UPCYou | $2M | -0.0 | — | — | 35.3% | -16.3% | -7.2% | -7.8% | — |
 HCWB | $2M | -0.1 | — | — | 20.0% | -20757.6% | -287.9% | -171.1% | — |
 XTLB | $279464 | -0.3 | — | — | 0.7% | -481.6% | -26.8% | -54.1% | — |
 NUVB | $2B | -9.3 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 CPRX | $4B | 18.7 | 10.6 | 18.4 | 85.2% | 43.8% | 25.5% | 83.8% | 0.0 |
 TLPH | $46M | -3.2 | — | — | 100.0% | -48157.1% | -114.2% | -86.8% | — |
 SIGA | $310M | 13.1 | 6.4 | 7.2 | 68.6% | 25.1% | 11.2% | 33.7% | 0.0 |
 HROW | $2B | -306.2 | 30.9 | 37.2 | 75.1% | 14.2% | -8.5% | 12.0% | 4.4 |
 MCK | $90B | 19.6 | 13.2 | 15.8 | 3.6% | 1.6% | — | 254.1% | 1.2 |
 CAH | $52B | 34.4 | 18.8 | 28.2 | 3.7% | 1.0% | — | 3378.7% | 3.0 |
 HSIC | $9B | 24.4 | 11.9 | 16.0 | 29.1% | 5.7% | 8.3% | 7.1% | 3.4 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
UPC — Frequently Asked Questions
Quick answers to the most common questions about buying UPC stock.
What is Universe Pharmaceuticals Inc.'s P/E ratio?
Universe Pharmaceuticals Inc.'s current P/E ratio is -0.0x. The historical average is 4.1x.
What is Universe Pharmaceuticals Inc.'s ROE?
Universe Pharmaceuticals Inc.'s return on equity (ROE) is -7.2%. The historical average is 20.3%.
Is UPC stock overvalued?
Based on historical data, Universe Pharmaceuticals Inc. is trading at a P/E of -0.0x. Compare with industry peers and growth rates for a complete picture.
What are Universe Pharmaceuticals Inc.'s profit margins?
Universe Pharmaceuticals Inc. has 35.3% gross margin and -16.3% operating margin.